CN109641887B - 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 - Google Patents

可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 Download PDF

Info

Publication number
CN109641887B
CN109641887B CN201780051410.0A CN201780051410A CN109641887B CN 109641887 B CN109641887 B CN 109641887B CN 201780051410 A CN201780051410 A CN 201780051410A CN 109641887 B CN109641887 B CN 109641887B
Authority
CN
China
Prior art keywords
compound
cancer
formula
salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780051410.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109641887A (zh
Inventor
马修·布莱恩·博克瑟
王晓东
凯勒·瑞恩·布里马科姆
曼迪·伊雷妮·艾米丽·戴维斯
方育红
马修·霍尔
阿吉特·贾达夫
苏伦德拉·卡拉瓦迪
刘莉
纳塔利娅·马丁内斯
安德鲁·路易斯·麦基弗
拉詹·普拉加尼
杰森·马修·罗德
安东·西梅奥诺夫
赵炜
沈敏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
US Department of Health and Human Services
Original Assignee
University of North Carolina at Chapel Hill
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill, US Department of Health and Human Services filed Critical University of North Carolina at Chapel Hill
Publication of CN109641887A publication Critical patent/CN109641887A/zh
Application granted granted Critical
Publication of CN109641887B publication Critical patent/CN109641887B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201780051410.0A 2016-06-22 2017-06-21 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物 Active CN109641887B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353298P 2016-06-22 2016-06-22
US62/353,298 2016-06-22
PCT/US2017/038549 WO2017223202A1 (en) 2016-06-22 2017-06-21 Thiazole derivatives useful as mutant idh1 inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
CN109641887A CN109641887A (zh) 2019-04-16
CN109641887B true CN109641887B (zh) 2022-09-20

Family

ID=59276859

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780051410.0A Active CN109641887B (zh) 2016-06-22 2017-06-21 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物

Country Status (8)

Country Link
US (1) US10836759B2 (enExample)
EP (1) EP3475276B1 (enExample)
JP (1) JP6987798B2 (enExample)
CN (1) CN109641887B (enExample)
AU (1) AU2017281088B2 (enExample)
CA (1) CA3028999A1 (enExample)
ES (1) ES2880347T3 (enExample)
WO (1) WO2017223202A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2961807A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2953347T3 (es) 2014-09-19 2023-11-10 Forma Therapeutics Inc Derivados de piridin-2(1H)-ona quinolinona como inhibidores de isocitrato deshidrogenasa mutante
JP6648116B2 (ja) 2014-09-19 2020-02-14 フォーマ セラピューティクス，インコーポレイテッド 変異イソクエン酸デヒドロゲナーゼ阻害剤としてのキノリノンピリミジン組成物
AU2015317327B9 (en) 2014-09-19 2020-04-09 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US9624175B2 (en) 2015-04-21 2017-04-18 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
PT3720442T (pt) 2018-05-16 2023-03-13 Forma Therapeutics Inc Inibição de idh-1 mutante
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557A (zh) * 2009-03-13 2013-03-20 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
WO2016106331A1 (en) * 2014-12-22 2016-06-30 The United States Of America Mutant idh1 inhibitors useful for treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102985557A (zh) * 2009-03-13 2013-03-20 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
CN105209460A (zh) * 2013-03-14 2015-12-30 诺华股份有限公司 作为突变idh抑制剂的3-嘧啶-4-基-噁唑烷-2-酮化合物
WO2016106331A1 (en) * 2014-12-22 2016-06-30 The United States Of America Mutant idh1 inhibitors useful for treating cancer
CN107428690A (zh) * 2014-12-22 2017-12-01 美国政府健康及人类服务部 可用于治疗癌症的突变idh1抑制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase;Zheng, BS et al.;《ACS MEDICINAL CHEMISTRY LETTERS》;20130503;第4卷(第6期);第542-546页 *

Also Published As

Publication number Publication date
JP2019518770A (ja) 2019-07-04
CN109641887A (zh) 2019-04-16
EP3475276B1 (en) 2021-03-31
CA3028999A1 (en) 2017-12-28
US10836759B2 (en) 2020-11-17
US20190241551A1 (en) 2019-08-08
EP3475276A1 (en) 2019-05-01
WO2017223202A1 (en) 2017-12-28
JP6987798B2 (ja) 2022-01-05
ES2880347T3 (es) 2021-11-24
AU2017281088A1 (en) 2019-01-17
AU2017281088B2 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
CN109641887B (zh) 可用作用于治疗癌症的突变idh1抑制剂的噻唑衍生物
JP6901394B2 (ja) 癌の処置に有用な変異型ｉｄｈ１阻害剤
EP2396325B1 (en) Derivatives of azaindoles as inhibitors of protein kinases abl and src
JP2007501272A (ja) 置換イミダゾロピラジンおよびトリアゾロピラジン誘導体類：ｇａｂａａレセプタリガンド類
TW202200575A (zh) 一種免疫抑制劑、其製備方法和應用
Xue et al. Discovery of 4, 7-Diamino-5-(4-phenoxyphenyl)-6-methylene-pyrimido [5, 4-b] pyrrolizines as Novel Bruton’s Tyrosine Kinase Inhibitors
WO2018214866A1 (zh) 一种氮杂芳基衍生物、其制备方法和在药学上的应用
WO2021126923A1 (en) Cd206 modulators their use and methods for preparation
US20210139492A1 (en) Furoquinolinediones as inhibitors of tdp2
JP2007500130A (ja) ベンゾジアゼピン受容体リガンドである、イミダゾ−ピリミジン及びトリアゾロ−ピリミジン
JPWO2013081094A1 (ja) イミダゾ［１，２−ａ］ピリジン誘導体及びその医薬用途
US20240190864A1 (en) Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF
JP2023512482A (ja) Ｆｇｆｒキナーゼ阻害剤としてのピリダジンおよび１，２，４－トリアジン誘導体
CN103664903A (zh) 苯氮卓类化合物及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant